Results 21 to 30 of about 23,620 (209)

Fixed combination of lercanidipine and enalapril in the management of hypertension; focus on patient preference and adherence [Corrigendum] [PDF]

, 2012
Borghi C, Santi F.Patient Preference and Adherence. 2012;6:449–455. On page 452, Table 1: Effect of fixed association of enalapril–lercanidipine on blood pressure control.
Borghi C, SANTI, FRANCESCA, Santi F, BORGHI, CLAUDIO   +3 more
core   +1 more source

Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in Ayder Comprehensive Specialized Hospital: a cross-sectional study

BMC Research Notes, 2018
Background Angiotensin-converting enzyme inhibitors have morbidity and mortality benefits in heart failure. Failure to optimize treatment using these medications increases hospitalizations, worsens signs and symptoms of heart failure, and reduces the ...
Tesfay Mehari Atey, Tsegay Teklay, Solomon Weldegebreal Asgedom, Haftay Berhane Mezgebe, Gebrehiwot Teklay, Molla Kahssay   +5 more
doaj   +1 more source

Effect of enalapril in cisplatin-induced nephrotoxicity in rats; gender-related difference

Advanced Biomedical Research, 2016
Background: The function of renin angiotensin system (RAS) is gender-related, and this system affects cisplatin (CP)-induced nephrotoxicity. In this study, we compared the effect of enalapril as an angiotensin-converting enzyme (ACE) inhibitor on CP ...
Zohreh Zamani, Mehdi Nematbakhsh, Fatemeh Eshraghi-Jazi, Ardeshir Talebi, Sima Jilanchi, Mitra Navidi, Soheila Shirdavani, Farzaneh Ashrafi   +7 more
doaj   +1 more source

Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2 [PDF]

, 2009
Angiotensin-converting enzyme (ACE) 2 is a recently identified homologue of ACE. There is great interest in the therapeutic benefit for ACE2 overexpression in the heart.
Smith, Godfrey, McBride, Martin, Graham, Delyth, Nicklin, Stuart A., Masson, Rachel, Craig, Margaret Anne, Gregorevic, Paul, Napoli, Claudio, Dominiczak, Anna F., Allen, James M., Baker, Andrew H., Gilday, Kirsten, Chamberlain, Jeffrey S.   +12 more
core   +1 more source

Pharmacology of enalapril in children: a review [PDF]

, 2020
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that is used for the treatment of (paediatric) hypertension, heart failure and chronic kidney diseases.
Dalinghaus, Michiel, Smeets, Nori, Walsh, J. (Jennifer), Wildt, S.N. (Saskia) de, Male, C, Laër, S. (Stephanie), Laer, Stephanie, Schreuder, MF (Michiel), Male, Christoph, Walsh, J, Lagler, Florian, Smeets, NJL, Lagler, F.B. (Florian B.), Schreuder, M.F. (Michiel), Male, C. (Christoph), Dalinghaus, M., Walsh, Jennifer, Schreuder, Michiel, Dalinghaus, M. (Michiel), Lagler, FB, de Wildt, Saskia, Laer, S, Smeets, N.J.L. (Nori J.L.)   +22 more
core   +1 more source

Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice

Frontiers in Physiology, 2022
Background: Diabetic kidney disease is the leading cause of end-stage renal disease. Administration of ACE inhibitors or/and SGLT2 inhibitors show renoprotective effects in diabetic and other kidney diseases.
Hannah Kroeger, Friederike Kessel, Jan Sradnick, Vladimir Todorov, Florian Gembardt, Christian Hugo   +5 more
doaj   +1 more source

Angiotensin-Converting Enzyme Inhibitor (ACEI)-Mediated Amelioration in Renal Fibrosis Involves Suppression of Mast Cell Degranulation

Kidney & Blood Pressure Research, 2016
Background/Aims: The mechanism by which angiotensin-converting enzyme inhibitors (ACEIs) attenuate renal fibrosis has not been fully uncovered. Methods: Renal fibrosis in rats was triggered by unilateral ureteral obstruction (UUO) and treated with ...
Nan Sun, Lei Zhai, Hui Li, Li-Hua Shi, Zhi Yao, Bo Zhang   +5 more
doaj   +1 more source

Transient Exposure of Enalapril Normalizes Prenatal Programming of Hypertension and Urinary Angiotensinogen Excretion. [PDF]

PLoS ONE, 2015
Maternal low protein diet programs offspring to develop hypertension as adults. Transient exposure to angiotensin converting enzyme inhibitors or angiotensin II receptor blockers can result in improvement in hypertension. Male rats whose mothers received
Asifhusen Mansuri, Ayah Elmaghrabi, Susan K Legan, Jyothsna Gattineni, Michel Baum   +4 more
doaj   +1 more source

Effect of Compound 1 or Enalapril or combination of Compound 1 and Enalapril on MBP and HR.

, 2022
Green arrow indicates start of the treatments of Vehicle or Compound 1 or Enalapril or combination of Compound 1 and Enalapril for 6 months. Blue arrow indicates Compound 1 dose was switched from 1 mg/kg/day to 3 mg/kg/day.
Maarten Hoek (6611984), Ken Lin (9358913), Gayathri Swaminath (133141), Xiaoyan Zhou (228434), Jeff Grein (347339), Yinhong Chen (9248645), Yang Liu (4829), Lufei Hu (3187827), Jason Cox (7550522), Wendy Blumenschein (11764706)   +9 more
core   +1 more source

COMPARISON OF ENALAPRIL AND PERINDOPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION AND LEFT VENTRICLE SYSTOLIC DYSFUNCTION

Рациональная фармакотерапия в кардиологии, 2016
Aim. To compare efficacy of enalapril and perindopril in patients with arterial hypertension (HT) and left ventricle systolic dysfunction.Material and methods.
Yu. I. Grinshtein, O. L. Barbarash, D. A. Yakhontov, A. E. Popelysheva, V. V. Shabalin, N. B. Osetrova   +5 more
doaj   +1 more source